| Tagraxofusp studied in …STUDIED_INderived20 of 20show fewer |
|---|
| → studied in | NCT04216524Phase 2 · recruiting Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm · 20 trials list this drug (12 active) | — | — | Blastic Plasmacytoid Dendritic Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07785154recruiting A Registry-study of ELZONRIS in Participants With BPDCN · 20 trials list this drug (12 active) | — | — | Blastic Plasmacytoid Dendritic Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06456463Phase 2 · active not recruiting A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy · 20 trials list this drug (12 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05233618Phase 1 · active not recruiting Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) · 20 trials list this drug (12 active) | — | — | Acute Myeloid Leukemia,Chronic Myelomonocytic Leukemia,Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06498973Phase 1 · recruiting Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant · 20 trials list this drug (12 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05038592Phase 1/Phase 2 · active not recruiting Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes · 20 trials list this drug (12 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm,Chronic Myelomonocytic Leukemia,Chronic Myelomonocytic Leukemia-1+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05442216Phase 2 · recruiting Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents · 20 trials list this drug (12 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07007052Phase 2 · recruiting Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients · 20 trials list this drug (12 active) | — | — | Blastic Plasmacytoid Dendritic Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03113643Phase 1 · recruiting SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) · 20 trials list this drug (12 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia,Blastic Plasmacytoid Dendritic Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561152Phase 1/Phase 2 · recruiting Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML · 20 trials list this drug (12 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07148180Phase 1/Phase 2 · recruiting A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax · 20 trials list this drug (12 active) | — | — | Liquid Tumor,Leukemia,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05032183Phase 1/Phase 2 · terminated Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma · 20 trials list this drug (12 active) | — | — | Lymphoblastic Lymphoma,Adult Lymphoblastic Lymphoma,B Acute Lymphoblastic Leukemia+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04342962Phase 2 · terminated Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia · 20 trials list this drug (12 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02268253Phase 1/Phase 2 · completed Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) · 20 trials list this drug (12 active) | — | — | Chronic Myelomonocytic Leukemia,Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05476770Phase 1 · recruiting Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies · 20 trials list this drug (12 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,B-Cell Malignant Neoplasm,Acute Lymphoblastic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02270463Phase 1/Phase 2 · terminated SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission · 20 trials list this drug (12 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02113982Phase 1/Phase 2 · completed Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia · 20 trials list this drug (12 active) | — | — | Acute Myeloid Leukemia,Blastic Plasmacytoid Dendritic Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04317781Phase 2 · terminated Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant · 20 trials list this drug (12 active) | — | — | Blastic Plasmacytoid Dendritic Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05720988Phase 1 · withdrawn Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia · 20 trials list this drug (12 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00397579Phase 1/Phase 2 · completed DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes · 20 trials list this drug (12 active) | — | — | Leukemia,Myelodysplastic Syndrome,Blastic Plasmacytoid Dendritic Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |